Here's Why Theravance Biopharma (TBPH) is a Strong Growth Stock

Core Insights - Zacks Premium offers various tools to enhance stock market investment confidence and knowledge [1][2] Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum methodologies, helping investors identify stocks likely to outperform the market in the next 30 days [3][4] - Each stock is rated from A to F, with A indicating the highest potential for outperformance [4] Value Score - The Value Style Score focuses on identifying undervalued stocks using financial ratios like P/E, PEG, and Price/Sales [4] Growth Score - The Growth Style Score emphasizes a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow [5] Momentum Score - The Momentum Style Score assesses stocks based on price trends and earnings outlook changes, helping investors capitalize on upward or downward price movements [6] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investing strategies [7] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +23.81% since 1988, significantly outperforming the S&P 500 [8][9] - There are over 800 top-rated stocks available, making it essential to use Style Scores to narrow down choices [9] Stock to Watch: Theravance Biopharma (TBPH) - Theravance Biopharma is a biopharmaceutical company focused on respiratory medicines, rated 2 (Buy) on the Zacks Rank with a VGM Score of A [12] - The company is particularly appealing to growth investors, with a Growth Style Score of A and a forecasted year-over-year earnings growth of 175% for the current fiscal year [13] - Recent upward revisions in earnings estimates and a strong average earnings surprise of +55.4% further enhance TBPH's investment appeal [13]